Finance

Lists
Q3 2026 earnings • released • EPS beat +128.03% • Revenue beat +7.03%
See results
A1RG34:BVMF
Argenx Se Bdr
R$162.13
0.00%
(0.00) 1D
Oct 16, 10:03:00 AM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for A1RG34...
Mkt. cap
48.73B
Avg. vol.
59.00
Volume
0.00
52-wk high
R$213.15
52-wk low
R$143.22
Shares outstanding
62.89M
No. of employees
2K
Mkt. cap
48.73B
Avg. vol.
59.00
Volume
0.00
52-wk high
R$213.15
52-wk low
R$143.22
Shares outstanding
62.89M
No. of employees
2K
News stories
From web sources and news partners
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About Argenx Se Bdr
CEO-
Employees1.86K
FoundedApr 25, 2008
Headquarters-
SectorBiotechnology
Websiteargenx.com
Last report
Oct 22, 2026
Fiscal period
Q3 2026
$7.80 / -$27.83
+128.03%beat
Revenue / Est. (USD)
1.75B / 1.64B
+7.03%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.15B
1.31B
1.31B
1.54B
Cost of goods sold
465.08M
521.40M
564.00M
631.00M
Cost of revenue
465.08M
521.40M
564.00M
631.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
336.29M
429.62M
355.00M
417.00M
Operating expense
336.29M
429.62M
355.00M
417.00M
Total operating expenses
801.37M
951.02M
919.00M
1.05B
Operating income
349.97M
359.56M
394.00M
493.00M
Other non operating income
-
-907.00K
-
-1.00M
EBT including unusual items
386.05M
403.29M
426.00M
531.00M
EBT excluding unusual items
386.05M
391.71M
426.00M
531.00M
Income tax expense
41.80M
-129.66M
60.00M
59.00M
Effective tax rate
10.83%
-32.15%
14.08%
11.11%
Other operating expenses
-
-
-
-
Net income
344.26M
532.95M
366.00M
472.00M
Net profit margin
29.90%
40.67%
27.88%
30.63%
Earnings per share
5.18
8.02
5.52
7.32
Interest and investment income
42.70M
44.95M
44.00M
48.00M
Interest expense
-993.00K
-
-1.00M
-1.00M
Net interest expenses
41.71M
44.95M
43.00M
47.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
350.35M
361.38M
395.82M
501.50M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps